About Immunomedics (NASDAQ:IMMU)
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-8.80645161290322
Forward P/E Ratio-17.06
Sales & Book Value
Annual Sales$3.09 million
Price / Sales878.79
Price / CashN/A
Book Value$0.10 per share
Price / Book163.80
Return on EquityN/A
Return on Assets-76.04%
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Thursday, February, 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.03. The biopharmaceutical company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.70 million. View Immunomedics' Earnings History.
Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2018?
3 equities research analysts have issued 12-month price targets for Immunomedics' shares. Their forecasts range from $15.00 to $27.00. On average, they anticipate Immunomedics' share price to reach $21.00 in the next year. View Analyst Ratings for Immunomedics.
Are investors shorting Immunomedics?
Immunomedics saw a increase in short interest in January. As of January 31st, there was short interest totalling 28,169,474 shares, an increase of 2.4% from the January 12th total of 27,496,613 shares. Based on an average daily volume of 2,437,956 shares, the short-interest ratio is presently 11.6 days. Approximately 20.7% of the shares of the company are sold short.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include FibroGen (FGEN), Anacor Pharmaceuticals (ANAC), Syneos Health (SYNH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Shire Viropharma (VPHM), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), Global Blood Therapeutics (GBT), Foundation Medicine (FMI), Puma Biotechnology (PBYI), Ironwood Pharmaceuticals (IRWD), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Crispr Therapeutics (CRSP), Intrexon (XON) and Arena Pharmaceuticals (ARNA).
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Behzad Aghazadeh Ph.D., Independent Chairman of the Board (Age 46)
- Michael F. Pehl, President, Chief Executive Officer, Director (Age 52)
- Michael R. Garone, Chief Financial Officer, Vice President - Finance (Age 59)
- David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director (Age 79)
- Brendan Delaney, Chief Commercial Officer
- Cynthia L. Sullivan, Director (Age 61)
- Scott A. Canute, Independent Director (Age 57)
- Peter Barton Hutt, Independent Director (Age 82)
- Khalid Islam Ph.D., Independent Director (Age 61)
- Brian A. Markison, Lead Independent Director (Age 58)
Who owns Immunomedics stock?
Immunomedics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.96%), ArrowMark Colorado Holdings LLC (3.15%), Palo Alto Investors LLC (2.88%), Jennison Associates LLC (1.20%), Victory Capital Management Inc. (0.73%) and Geode Capital Management LLC (0.60%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Who sold Immunomedics stock? Who is selling Immunomedics stock?
Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Renaissance Technologies LLC, Deutsche Bank AG, Nexthera Capital LP, Gotham Asset Management LLC, Chicago Equity Partners LLC, EAM Investors LLC and Sphera Funds Management LTD.. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.
Who bought Immunomedics stock? Who is buying Immunomedics stock?
Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, ArrowMark Colorado Holdings LLC, Victory Capital Management Inc., Franklin Resources Inc., BlackRock Inc., Lyon Street Capital LLC, Ardsley Advisory Partners and Guggenheim Capital LLC. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy Immunomedics stock?
Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of Immunomedics stock can currently be purchased for approximately $16.38.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $2.49 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Immunomedics employs 138 workers across the globe.
How can I contact Immunomedics?
Immunomedics' mailing address is 300 the American Rd, MORRIS PLAINS, NJ 07950-2460, United States. The biopharmaceutical company can be reached via phone at +1-973-6058200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (IMMU)MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Immunomedics (NASDAQ:IMMU) Earnings History and Estimates Chart
Immunomedics (NASDAQ IMMU) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q1 2018||($0.10)||($0.16)||$0.90 million||$0.69 million||View||N/A|
|8/16/2017||Q4 2017||($0.12)||($0.25)||$0.75 million||$0.64 million||View||N/A|
|5/10/2017||Q3 2017||($0.13)||($0.22)||$0.90 million||$1.32 million||View||N/A|
|2/9/2017||Q2 2017||($0.13)||($0.16)||$0.70 million||$0.38 million||View||Listen|
|11/2/2016||Q117||($0.14)||($0.17)||$0.70 million||$0.74 million||View||N/A|
|8/17/2016||Q416||($0.11)||($0.17)||$0.90 million||$0.93 million||View||Listen|
|5/4/2016||Q3||($0.13)||($0.15)||$0.70 million||$0.90 million||View||N/A|
|2/3/2016||Q216||($0.14)||($0.15)||$1.40 million||$0.67 million||View||N/A|
|11/4/2015||Q116||($0.14)||($0.16)||$1.23 million||$0.73 million||View||N/A|
|8/19/2015||Q415||($0.13)||($0.13)||$1.13 million||$2.40 million||View||Listen|
|5/6/2015||Q3 2015||($0.13)||($0.13)||$1.07 million||$1.18 million||View||N/A|
|2/4/2015||Q215||($0.13)||($0.12)||$1.73 million||$1.00 million||View||N/A|
|11/5/2014||Q1 2015||($0.12)||($0.13)||$1.18 million||$1.07 million||View||N/A|
|8/25/2014||Q414||($0.13)||($0.13)||$1.20 million||$1.20 million||View||N/A|
|5/7/2014||Q3 2014||($0.12)||$0.02||$1.13 million||$1.15 million||View||N/A|
|2/10/2014||Q214||($0.10)||($0.10)||$1.20 million||$1.20 million||View||N/A|
|11/4/2013||Q1 2014||($0.10)||($0.05)||$1.51 million||$5.50 million||View||N/A|
|8/22/2013||Q4 2013||($0.12)||($0.09)||$0.81 million||$1.40 million||View||N/A|
|5/8/2013||Q3 2013||($0.10)||$0.11||$0.97 million||$1.70 million||View||N/A|
Immunomedics (NASDAQ:IMMU) Earnings Estimates
2018 EPS Consensus Estimate: ($0.56)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com
Immunomedics (NASDAQ IMMU) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 72.69%
Immunomedics (NASDAQ IMMU) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/20/2017||Brian A Markison||Director||Sell||8,390||$11.89||$99,757.10||99,178|| |
|11/15/2017||Behzad Aghazadeh||Insider||Buy||1,325,000||$10.47||$13,872,750.00|| |
|11/14/2017||Venbio Select Advisor Llc||Director||Buy||1,150,000||$10.39||$11,948,500.00|| |
|9/1/2017||David M. Goldenberg||Insider||Sell||20,000||$12.64||$252,800.00|| |
|8/28/2017||Cynthia L. Goldenberg||Director||Sell||40,000||$10.72||$428,800.00|| |
|8/23/2017||Cynthia L. Goldenberg||Director||Sell||40,000||$9.24||$369,600.00|| |
|8/24/2016||Don C Stark||Director||Sell||9,900||$2.97||$29,403.00||55,848|| |
|8/23/2016||Mary E Paetzold||Director||Sell||15,000||$2.98||$44,700.00||82,474|| |
|6/13/2016||Cynthia L Goldenberg||CEO||Sell||371,990||$3.03||$1,127,129.70||650,396|| |
|6/8/2016||Cynthia L Goldenberg||CEO||Sell||41,441||$3.62||$150,016.42||703,029|| |
|6/8/2016||David M Goldenberg||Chairman||Sell||353,010||$3.88||$1,369,678.80||2,602,063|| |
|6/7/2016||Cynthia L Goldenberg||CEO||Sell||4,600||$4.01||$18,446.00||703,029|| |
|6/7/2016||David M Goldenberg||Chairman||Sell||12,300||$3.98||$48,954.00||2,602,063|| |
|6/6/2016||Cynthia L Goldenberg||CEO||Sell||63,959||$4.09||$261,592.31||703,029|| |
|6/6/2016||David M Goldenberg||Chairman||Sell||110,322||$4.09||$451,216.98||2,602,063|| |
|6/15/2015||David M Goldenberg||Chairman||Sell||210,991||$4.08||$860,843.28|| |
|6/12/2015||Brian A Markison||Director||Sell||5,564||$4.22||$23,480.08|| |
|6/12/2015||David M Goldenberg||Chairman||Sell||359,653||$4.32||$1,553,700.96|| |
|6/9/2015||Mary E Paetzold||Director||Sell||4,677||$4.60||$21,514.20|| |
|6/5/2015||Don C Stark||Director||Sell||5,732||$4.14||$23,730.48|| |
|12/11/2014||Mary E Paetzold||Director||Sell||10,000||$4.71||$47,100.00|| |
|12/9/2014||Don C Stark||Director||Sell||5,500||$4.51||$24,805.00|| |
|9/13/2013||Don Stark||Director||Sell||10,000||$6.08||$60,800.00||22,000|| |
Immunomedics (NASDAQ IMMU) News Headlines
|Immunomedics (IMMU) Upgraded by TheStreet to C-|
www.americanbankingnews.com - February 18 at 9:22 PM
|Zacks Investment Research Downgrades Immunomedics (IMMU) to Sell|
www.americanbankingnews.com - February 17 at 6:56 AM
|Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference|
finance.yahoo.com - February 15 at 8:20 AM
|Reviewing Immunomedics (IMMU) and Arsanis (ASNS)|
www.americanbankingnews.com - February 15 at 3:18 AM
|Blog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry Disease|
finance.yahoo.com - February 14 at 9:33 AM
|Immunomedics (IMMU) Raised to "Buy" at BidaskClub|
www.americanbankingnews.com - February 11 at 8:10 AM
|Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - February 10 at 1:58 PM
|Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update|
finance.yahoo.com - February 9 at 9:35 AM
|Immunomedics reports 2Q loss|
finance.yahoo.com - February 9 at 9:35 AM
|Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018|
finance.yahoo.com - February 6 at 9:31 AM
|Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU)|
www.americanbankingnews.com - January 31 at 5:12 PM
|Immunomedics (IMMU) Price Target Raised to $27.00|
www.americanbankingnews.com - January 28 at 5:34 PM
|BidaskClub Upgrades Immunomedics (IMMU) to Strong-Buy|
www.americanbankingnews.com - January 28 at 8:54 AM
|Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU)|
www.americanbankingnews.com - January 28 at 7:18 AM
|Q3 2018 EPS Estimates for Immunomedics, Inc. Lifted by Analyst (IMMU)|
www.americanbankingnews.com - January 26 at 10:22 AM
|Interesting IMMU Put And Call Options For March 16th|
www.nasdaq.com - January 24 at 4:17 PM
|Immunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - January 16 at 2:08 PM
|Short Sellers Fueling Runaway Bull Market By Racing To Buy Back Stocks|
www.forbes.com - January 15 at 3:27 PM
|Short Interest in Immunomedics, Inc. (IMMU) Expands By 6.3%|
www.americanbankingnews.com - January 12 at 3:14 AM
|BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer|
www.reuters.com - January 11 at 8:50 AM
|Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer|
finance.yahoo.com - January 11 at 8:50 AM
|Today’s Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics|
finance.yahoo.com - January 10 at 9:28 AM
|Immunomedics (IMMU) Enters Royalty Funding and Stock Purchase Agreements with Royalty Pharma Worth $250M|
www.streetinsider.com - January 9 at 9:46 AM
|Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million - GlobeNewswire (press release)|
globenewswire.com - January 8 at 3:32 PM
|Immunomedics (IMMU) Downgraded by ValuEngine to Sell|
www.americanbankingnews.com - January 5 at 11:22 PM
|Immunomedics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - January 5 at 9:24 AM
|Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference|
finance.yahoo.com - January 4 at 9:15 AM
|Immunomedics (IMMU) and Its Rivals Financial Review|
www.americanbankingnews.com - January 2 at 5:28 AM
|Head to Head Contrast: Immunomedics (IMMU) & Its Peers|
www.americanbankingnews.com - January 1 at 5:10 PM
|Harry Boxer: These two marijuana stocks are climbing higher|
finance.yahoo.com - December 28 at 3:01 PM
|Immunomedics (IMMU) Upgraded to Buy by BidaskClub|
www.americanbankingnews.com - December 22 at 8:18 PM
|ETFs with exposure to Immunomedics, Inc. : December 22, 2017|
finance.yahoo.com - December 22 at 3:49 PM
|Immunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - December 22 at 2:50 PM
|BlackBerry Among Four Stocks Breaking Out|
finance.yahoo.com - December 21 at 3:29 PM
|Passive Investors And Their Role In Activism For 2018|
www.forbes.com - December 21 at 9:04 AM
|First Week of August 2018 Options Trading For Immunomedics (IMMU)|
www.nasdaq.com - December 20 at 3:26 PM
|SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of ... - PR Newswire (press release)|
www.prnewswire.com - December 14 at 9:00 AM
|SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors|
finance.yahoo.com - December 13 at 9:12 AM
|ETFs with exposure to Immunomedics, Inc. : December 11, 2017|
finance.yahoo.com - December 11 at 3:25 PM
|Immunomedics (IMMU) & Its Peers Head to Head Review|
www.americanbankingnews.com - December 10 at 5:20 PM
|Immunomedics' Data Is Good News for Seattle Genetics, Too|
finance.yahoo.com - December 8 at 9:10 AM
|Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017|
finance.yahoo.com - December 8 at 9:10 AM
|Immunomedics (IMMU) Updated Results With Sacituzumab Govitecan In Patients With Relapsed Or Refractory mTNBC|
www.streetinsider.com - December 7 at 3:29 PM
|Why Immunomedics, Inc. Is Soaring Today - Motley Fool|
www.fool.com - December 7 at 9:08 AM
|Today’s Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals|
finance.yahoo.com - December 7 at 9:08 AM
|Why Immunomedics, Inc. Is Soaring Today|
finance.yahoo.com - December 7 at 9:08 AM
|Immunomedics rallies 17% ahead of data release on lead candidate IMMU-132|
seekingalpha.com - December 6 at 12:23 PM
|Immunomedics (IMMU) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - December 4 at 9:38 PM
|Jim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics - Benzinga|
www.benzinga.com - December 1 at 11:46 AM
|ETFs with exposure to Immunomedics, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 3:27 PM
Immunomedics (NASDAQ:IMMU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Immunomedics (NASDAQ:IMMU) Income Statement, Balance Sheet and Cash Flow Statement
Immunomedics (NASDAQ IMMU) Stock Chart for Wednesday, February, 21, 2018